Trever Bivona, M.D. Ph.D. is a cell and molecular biologist and a laboratory-based physician scientist at the University of California, San Francisco where he is a medical oncologist and Professor of Medicine and of Cellular and Molecular Pharmacology. He is a cancer biologist who leads a research program focused on signal transduction and cancer genetics and the molecular basis of tumor initiation, evolution, and drug resistance. A major area of interest is the function and therapeutic targeting of oncogenic receptor tyrosine kinases (RTKs) such as EGFR and ALK as well as RAS GTPase signaling. A recent discovery and area of interest is the role of membraneless cytoplasmic biomolecular condensates formed by certain oncogenic RTKs in driving oncogenic signaling through RAS and other proteins to promote cancer. The overall goal of this research program is to understand the regulatory principles underlying cancer cell signaling and tumor evolution to improve cancer therapy and patient survival and quality of life. Dr. Bivona received a NIH Director’s New Innovator Award and is an elected member of the American Society for Clinical Investigation. Dr. Bivona is currently Principal Investigator of the NIH/NCI U54 Bay Area Drug Resistance and Sensitivity Center and is a Chan-Zuckerberg Biohub Senior Investigator.